Distribution of pulmonary infection pathogens after lung cancer chemotherapy and diagnostic values of serum cytokeratin 19 fragment antigen, high mobility group box 1 protein and soluble hemoglobin scavenger receptor

ZHENG Junqi; LIU Xiangyan

doi:10.7619/jcmp.20241847

Journal of Clinical Medicine in Practice > 2024 > 28(14): 7-11. > DOI: 10.7619/jcmp.20241847

ZHENG Junqi, LIU Xiangyan. Distribution of pulmonary infection pathogens after lung cancer chemotherapy and diagnostic values of serum cytokeratin 19 fragment antigen, high mobility group box 1 protein and soluble hemoglobin scavenger receptor[J]. Journal of Clinical Medicine in Practice, 2024, 28(14): 7-11. DOI: 10.7619/jcmp.20241847

Citation:

PDF (923 KB)

Distribution of pulmonary infection pathogens after lung cancer chemotherapy and diagnostic values of serum cytokeratin 19 fragment antigen, high mobility group box 1 protein and soluble hemoglobin scavenger receptor

ZHENG Junqi,
LIU Xiangyan^,

Qilu Medical College of Shandong University, Jinan, Shandong, 250012

More Information

Received Date: May 05, 2024
Revised Date: June 26, 2024
Available Online: July 19, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the distribution of pathogens causing pulmonary infection after lung cancer chemotherapy and the changes and diagnostic value of serum cytokeratin 19 fragment antigen (CYFRA21-1), high mobility group box 1 protein (HMGB1), and soluble hemoglobin scavenger receptor (sCD163) levels.
Methods
A total of 83 lung cancer patients with chemotherapy from July 2022 to November 2023 were divided into non-infected group (n=43) and infected group (n=40) based on their pulmonary infection status, sputum samples were collected from lung cancer chemotherapy patients, and the source of the samples was recorded for bacterial identification.The changes in serum CYFRA21-1, HMGB1 and sCD163 levels were compared between the two groups; a multivariate Logistic regression model was used to analyze the factors influencing pulmonary infection after lung cancer chemotherapy; the diagnostic values of serum CYFRA21-1, HMGB1 and sCD163 levels for pulmonary infection after lung cancer chemotherapy were analyzed.
Results
Among the 83 patients with lung cancer chemotherapy, 40 cases had pulmonary infections; a total of 55 strains of pathogens were detected, including 34 Gram-negative bacteria and 18 Gram-positive bacteria, accounting for 61.82% and 32.73% respectively, while only 3 strains of fungi were detected, accounting for 5.45%.Serum levels of CYFRA21-1, HMGB1 and sCD163 in the infected group were significantly higher than those in the non-infected group (P < 0.05).Age, history of lung diseases, CYFRA21-1, HMGB1 and sCD163 were factors influencing pulmonary infection in patients with lung cancer chemotherapy (P < 0.05).The areas under the curve for the diagnostic value of serum CYFRA21-1, sCD163 and HMGB1 levels for pulmonary infection after lung cancer chemotherapy were 0.677, 0.763 and 0.819, respectively (P < 0.05).
Conclusion
The main pathogens causing pulmonary infection after lung cancer chemotherapy are Gram-negative bacteria, and the serum levels of CYFRA21-1, HMGB1 and sCD163 increase significantly, which can be used as biological indicators for early diagnosis and assessment of infection.

FullText(HTML)

References (25)

References

[1]	杜晓丹, 徐维国, 朱静, 等. 嘌呤能型2受体家族X7嘌呤受体高表达与可切除非小细胞肺癌患者临床病理特征及预后的相关性研究[J]. 实用临床医药杂志, 2022, 26(10): 77-82. doi: 10.7619/jcmp.20214728
[2]	胡长青, 李彬, 王立红, 等. 周围型肺癌化疗患者经外周静脉穿刺中心静脉置管后导管相关感染的危险因素分析[J]. 实用临床医药杂志, 2022, 26(15): 40-44. doi: 10.7619/jcmp.20220461
[3]	YE W H, LV H Y, ZHANG Q X, et al. A cisplatin and disulphiram co-loaded inclusion complex overcomes drug resistance by inhibiting cancer cell stemness in non-small cell lung cancer[J]. J Drug Target, 2024, 32(2): 159-171. doi: 10.1080/1061186X.2023.2298844
[4]	张俐丽, 冯国琴. 个体化预测非小细胞肺癌患者化疗期间肺部感染风险Nomogram模型的建立与验证[J]. 中国感染控制杂志, 2022, 21(2): 171-179. https://www.cnki.com.cn/Article/CJFDTOTAL-GRKZ202202010.htm
[5]	王临英, 朱丹, 陈慧, 等. 肺癌化疗患者肺部感染病原学及肺炎克雷伯菌分离株耐药基因[J]. 中华医院感染学杂志, 2024, 34(2): 182-185. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202402005.htm
[6]	ROLFO C, MESHULAMI N, RUSSO A, et al. Lung cancer and severe acute respiratory syndrome coronavirus 2 infection: identifying important knowledge gaps for investigation[J]. J Thorac Oncol, 2022, 17(2): 214-227. doi: 10.1016/j.jtho.2021.11.001
[7]	韩卫, 李海泉, 郭毅, 等. 胃泌素释放肽前体、神经元特异性烯醇化酶、细胞角蛋白19片段抗原21-1、鳞状上皮细胞癌抗原及人附睾蛋白4在肺癌诊断中的应用价值[J]. 肿瘤研究与临床, 2023, 35(2): 86-91. doi: 10.3760/cma.j.cn115355-20220513-00296
[8]	CUI Y M, WU X J, JIN J, et al. CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis[J]. Mol Cancer, 2023, 22(1): 179. doi: 10.1186/s12943-023-01888-7
[9]	支修益, 杨跃, 王长利, 等. 原发性肺癌诊疗规范(2015年版): 外科部分[J]. 中国医学前沿杂志: 电子版, 2015, 7(2): 28-31. doi: 10.3969/j.issn.1674-7372.2015.02.011
[10]	吴冰, 孙圆满, 姜红梅, 等. CEA、VEGF、MMP-9表达与肺癌并发肺部感染的相关性[J]. 中华医院感染学杂志, 2023, 9(2): 181-184. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202302005.htm
[11]	SUN D Q, LI H, CAO M M, et al. Cancer burden in China: trends, risk factors and prevention[J]. Cancer Biol Med, 2020, 17(4): 879-895. doi: 10.20892/j.issn.2095-3941.2020.0387
[12]	刘衍彤, 李雪菲, 窦晓忱, 等. 非小细胞肺癌甲基转移酶DNMT3B基因多态性与化疗期间肺部感染易感性的关联[J]. 中华医院感染学杂志, 2023, 9(8): 1148-1152. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202308006.htm
[13]	何锋, 陈新富, 王小英, 等. 炎症标志物对胸腔镜肺癌根治术后患者肺部感染早期预测准确性的分析[J]. 实用癌症杂志, 2022, 37(7): 1174-1177. doi: 10.3969/j.issn.1001-5930.2022.07.032
[14]	桑圣梅, 王丽华, 陈金亮, 等. 肺癌化疗患者肺部感染病原学及其与SP-D基因多态性的关联性[J]. 中华医院感染学杂志, 2022, 32(7): 976-980. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202207004.htm
[15]	郑娉婷, 纪超娜, 王逸如, 等. 肺癌患者术后肺部感染预防护理方案的构建及验证[J]. 中华护理杂志, 2024, 59(7): 820-827. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHL202407006.htm
[16]	薛刚, 郭华, 白洁. 肺癌化疗并发肺部感染患者血清炎性因子水平检测的意义[J]. 中国肿瘤临床与康复, 2022, 8(2): 167-170. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK202202010.htm
[17]	WANG K L, SHAN S, WANG S Q, et al. HMGB1-containing nucleosome mediates chemotherapy-induced metastasis of human lung cancer[J]. Biochem Biophys Res Commun, 2018, 500(3): 758-764. doi: 10.1016/j.bbrc.2018.04.150
[18]	REN Y H, CAO L M, WANG L M, et al. Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFκB signaling[J]. Cell Death Dis, 2021, 12(10): 858. doi: 10.1038/s41419-021-04150-4
[19]	张帆, 周勇锋, 辛伟. 肺癌化疗患者并发细菌性肺部感染的病原菌特点和血清MMP-9、sTREM-1、sCD163变化情况及其诊断价值[J]. 贵州医药, 2022, 46(7): 1130-1131. doi: 10.3969/j.issn.1000-744X.2022.07.069
[20]	付文慧, 刘雯, 黄毅力, 等. 中晚期非小细胞肺癌调强放疗联合化疗前后血清VEGF、CEA、NSE和CYFRA21-1的表达及其临床意义[J]. 现代医学, 2023, 51(4): 501-505. doi: 10.3969/j.issn.1671-7562.2023.04.012
[21]	张涛, 张波, 张学伟, 等. 血清CYFRA21-1、CEA、SCC、HE4、ProGRP对肺癌早期诊断及病理类型鉴别的临床价值[J]. 海南医学, 2023, 34(9): 1281-1285. doi: 10.3969/j.issn.1003-6350.2023.09.015
[22]	刘鹭, 程建平, 金跃. 血清ProGRP、HE4、CA153、CEA和CYFRA21-1联合检测在肺部良恶性疾病中的临床价值[J]. 标记免疫分析与临床, 2018, 25(1): 99-101, 112. https://www.cnki.com.cn/Article/CJFDTOTAL-BJMY201801025.htm
[23]	叶彬, 郝群, 茹小虎, 等. 肺癌患者术后肺部感染sTREM-1和sCD163与PCT变化研究[J]. 中华医院感染学杂志, 2019, 29(11): 1673-1676. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201911018.htm
[24]	吴小伟, 严加高, 李陶, 等. 肺癌术后肺部感染患者血浆sTREM-1、sCD163与PCT水平与疗效的关系[J]. 分子诊断与治疗杂志, 2021, 13(8): 1209-1213. doi: 10.3969/j.issn.1674-6929.2021.08.004
[25]	李永杰, 闫其星, 周源, 等. sTREM-1、HMGB1和内毒素对胸腔镜肺癌根治术后肺部感染的预测价值[J]. 临床和实验医学杂志, 2023, 22(10): 1065-1069. doi: 10.3969/j.issn.1671-4695.2023.10.015

Cited By

Cited by

Periodical cited type(1)

杜胜勇，周厚富，陈小艳. 螺旋CT联合胸部DR在早期肺部感染诊断中的应用. 中国防痨杂志. 2024(S2): 259-261 .

Other cited types(0)

Get Citation

PDF

XML

Article views (202) PDF downloads (24) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Distribution of pulmonary infection pathogens after lung cancer chemotherapy and diagnostic values of serum cytokeratin 19 fragment antigen, high mobility group box 1 protein and soluble hemoglobin scavenger receptor

Abstract

References

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Export File

Citation

Format

Content